Altimmune Inc (ALT)

[chmcnfunds]

Altimmune to Announce First Quarter 2018 Financial Results on May 16

By GlobeNewswire, May 08, 2018, 08:00:00 AM EDT

GAITHERSBURG, Md., May 08, 2018 (GLOBE NEWSWIRE) --

Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the first quarter ended March 31, 2018 before the market open and host a conference call on Wednesday, May 16.


Conference Call Details

Date: Wednesday, May 16

Time: 8:30am Eastern Time

Domestic: 888-394-8218

International: 323-701-0225

Conference ID: 1336227

Webcast: http://public.viavid.com/index.php?id=129546

Replays, Available through May 30th:

Domestic: 844-512-2921

International: 412-317-6671

Replay PIN: 1336227

About Altimmune

Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease including NasoVAX, a Phase 2 seasonal influenza vaccine candidate, and HepTcell, a Phase 1 immunotherapeutic candidate for the potential cure of chronic hepatitis B. The company also has two United States government funded, next-generation anthrax vaccine candidates that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines.

Contacts:

Bill Enright

President and CEO

Phone: [phone]

[e-mail]

Ashley Robinson

LifeSci Advisors, LLC

617-535-7742

[e-mail]

Source: Altimmune, Inc.